Group items tagged

In response to stakeholder feedback, the General Pharmaceutical Council (GPhC) is developing a streamlined, single route to registration that will replace the current multiple-pathway system for overseas pharmacists wishing to practice in Great Britain. This revised approach will include updated standards for the education and training of internationally qualified pharmacists, with all applicants still required to pass a registration assessment. The GPhC's Council intends to streamline the registration pathway, reducing the two-year process to one-year process. This new pathway will encompass both university study and in-practice training. Historically, pharmacists qualified within the European Economic Area (EEA) or European Free Trade Association (EFTA) have been eligible for qualification recognition in Great Britain. While this recognition has been extended until September 2028, the future requirement for EEA-qualified pharmacists to undergo the new registration route remains contingent on forthcoming government decisions. Initially, the GPhC had explored the development of three distinct registration routes for internationally-qualified pharmacists, "however decided to change this proposed approach after considering feedback from stakeholders."

Matthew Taylor, Chief Executive of the NHS Confederation, delivered a compelling speech at the NHS ConfedExpo 2024, emphasising the critical need for investment in community-based care and the revitalisation of primary care services. In his address, Taylor also criticised the current health policy as "not fit for purpose," calling for radical changes to shift the NHS from a reactive to a proactive health model. Addressing delegates at the Manchester event, Taylor highlighted the importance of shifting resources towards prevention and community services. Underscoring a strategic pivot from reactive to proactive health models, he said: "We must see action to fulfil the long-held vision of a health service that invests better upstream in prevention, in primary and in community-based care."

There is a clear opportunity for community pharmacists and their teams to lead best practice when it comes to supporting the ongoing health needs of older people. As the global population continues to age, the demand for specialised healthcare services tailored to the elderly is rapidly increasing. Community pharmacists, with their accessible locations and frequent interactions with patients, are uniquely positioned to play a pivotal role in addressing this growing need. The ageing population presents a complex set of health challenges, including multiple chronic conditions, polypharmacy, and increased susceptibility to adverse drug reactions. Community pharmacists, armed with their extensive knowledge of medications and their effects, can serve as the first line of defence in managing these issues. By leveraging their expertise, they can implement best practices that not only improve the quality of life for older individuals but also reduce the burden on the broader healthcare system. One of the primary areas where community pharmacists can make a significant impact is in medication management. As people age, they often find themselves taking multiple medications for various conditions. This polypharmacy can lead to dangerous drug interactions, side effects, and compliance issues. Community pharmacists can lead the way in implementing comprehensive medication reviews, ensuring that each patient's drug regimen is optimised for their specific needs and minimising potential risks.

Curaprox Curasept Mouthwash is for short term intensive use and contains 0.20% chlorhexidine. It offers strong anti-bacterial and plaque inhibiting action and helps to reduce gum disease and tooth decay.

A diabetes medicine, Mounjaro, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat overweight patients. The weight loss medication originally developed for Type 2 diabetes is now accessible to individuals aged 18 and over who are dealing with obesity and weight-related health issues. The active ingredient, tirzepatide, works by making the patient feel fuller and reducing food cravings. The injection helps individuals lose 20 per cent of their body weight, and are advised to follow a reduced-calorie diet and increase physical activity simultaneously. Although it is not authorised to use on the NHS as yet but future approvals can be predicted.

Louth and Horncastle's MP Victoria Atkins has taken the new role of Health Secretary today (13 November) amid the PM's cabinet reshuffle. Steve Barclay, the former Secretary of State for Health and Social Care was moved to become Environment Secretary after being assigned the role of Health Secretary. The following decision was made consequent to Steve Barclay being reassigned from the role. The news comes at a time when the NHS faces enduring challenges and industrial action, making this change particularly significant. MP Atkins is married to Paul Kenward, managing director of British Sugar, which also grows medicinal cannabis.

It has been reported that several Austrians have been taken to the hospital after injecting fake Ozempic, as confirmed by health regulator. Austria's Federal Office for Safety in Health Care (BASG) confirmed that the patients have suffered hypoglycaemia and seizures. It is believed that the injections contained insulin instead of the weight loss drug, semaglutide. The health regulator has urged doctors and patients to verify their medication stocks.

WBA, Boots parent company revealed the results for its fourth quarter of the financial year, showing three months to August 2023. The reports published on 12 October show the loss of at least $1bn following a net loss of $3.1bn on an annual basis. This marks a decrease compared to a profit of $4.3bn in the previous financial year. The loss was attributed in part to a $5.5 billion after-tax charge related to opioid claims and litigation during the period, as well as the comparison against a $2.5 billion after-tax gain from the company's investments in Village MD and Shields Health Solutions in the same period last year. Ginger Graham, WBA's Interim Chief Executive spoke about the company's performance and its dedication to their customers and patients.

The British Generic Manufacturers Association (BGMA) has warned that England's 42 integrated care boards (ICBs) may need to allocate an extra £37 million from their budgets annually for the next five years due to the spiralling tax rates. The government's Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) rebate rate increased more than five-fold in the past two years, the BGMA said in its white paper released on Monday (October 30). The report, conducted by consultancy firm Conclusio in consultation with local NHS leaders, examined the potential effects of the VPAS on ICB budgets. BGMA said that due to the elevated VPAS rate, each ICB in England will experience significant increases in expenses for branded generics and biosimilars annually - a consequence of reduced competition.

The Royal Pharmaceutical Society (RPS) has said that multi-buy deals on paracetamol violate the existing voluntary sales guidelines. The professional body is urging the government to pass legislation that prohibits retailers from making such offers on medicines for pain relief. They have also sent letters to MP Maria Caulfield who is the Minister for Mental Health and Women's Health. The Medicines and Healthcare Products Regulatory Agency (MHRA) is requesting to take action on the legislation at the earliest. The concern raised is that multi-buy offers such as 'buy one get one free' can encourage people to buy and store excess packs, which may lead to accidental or impulsive overdose.

Two Indian pharmaceutical companies, Cipla and Glenmark, are pulling back certain products from the American market due to manufacturing concerns, according to the US Food and Drug Administration (USFDA). A New Jersey-based subsidiary of Cipla is recalling 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution due to "short fill", news agency PTI reported, quoting the latest Enforcement Report issued by the US health regulator. Produced at the company's Indore SEZ plant, this medication is used to manage symptoms associated with lung diseases, such as asthma, chronic bronchitis and emphysema. Cipla USA decided to recall the affected lot following complaints of less fill volume in respule and few drops of liquid observed in the intact pouch, the USFDA said, adding that the drug maker initiated the Class II recall in the US market on March 26 this year.

The government has allocated an additional 350 medical school places in England, making a significant step in delivering the NHS Long Term Workforce Plan. Supported by more than £2.4 billion in government funding, the plan outlines the strategy for recruiting and retaining hundreds of thousands more staff over the next 15 years to deliver the future workforce the NHS requires. One of the key commitments of the NHS Long Term Workforce Plan is to double the number of medical school places in England to 15,000 by 2031. As part of the ongoing efforts to fulfill this pledge, the Office for Students (OfS) has designated 350 places for medical schools nationwide for the academic year 2025 to 2026, targeting under-doctored areas.

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised the public to exercise caution when buying anti-choking devices online, ensuring these products are purchased from reputable sellers. As estimated by the regulator, more than 10,000 counterfeit or unbranded anti-choking devices have been purchased by the public within the last two years through listings on online marketplaces such as Amazon and eBay, as well as drop-shipping websites. People are cautioned that the use of such products poses a substantial risk of failure in clearing blockages and could exacerbate the situation by pushing obstructions further down into the airway passage. Dr Alison Cave, MHRA Chief Safety Officer, said: "Buying anti-choking devices that do not have a valid UKCA or CE mark increases the risk of receiving a product which does not include appropriate instructions and is either fake or does not meet the UK's regulatory requirements. "These products do not meet our strict quality standards and may put your health and safety at significant risk by failing to resolve or even worsening choking incidents."

A new bill was introduced to Parliament on Wednesday (20 March) to prohibit the sale of tobacco to children under the age of 15, delivering on the Prime Minister's commitment to create a smokefree generation. The Tobacco and Vapes Bill aims to protect future generations from the harmful impacts of smoking, thereby saving thousands of lives and billions of pounds for the NHS. The bill will also introduce new powers to restrict vape flavours and packaging deliberately targeted towards children, as well as allow the government to change how they are displayed in shops, moving them out of sight of children and away from products that appeal to them, like sweets. Additionally, enforcement officers' powers will be strengthened with 'on the spot fines' of £100 to ensure compliance with the new laws. This complements the existing maximum fine of £2,500 that local authorities can already impose. It will also become illegal to provide free samples of vapes to children under the age of 18.

Part of a raft of National Health Services (NHS) measures which aim to support people to prevent or reduce incidence of type 2 diabetes and obesity, the NHS Digital Weight Management Programme has emerged as a beacon of success in the battle against obesity, with a recent study showcasing its effectiveness in aiding weight loss among participants. According to research published in The Obesity Journal, the programme has garnered significant traction, with over 63,000 individuals referred in its inaugural year. Encouragingly, half of those referred opted to enroll in the service, highlighting its appeal and accessibility. Among the 14,000 participants who completed the 12-week programme between April 2021 and March 2022, a notable average weight loss of 3.9kg (equivalent to 8.59lbs) was achieved. Even among those who did not complete the programme, an average weight loss of 2.2kg (approximately 4.85lbs) was observed.

In 2023, almost 14,000 people in England are estimated to have died due to excessive waits in emergency departments, averaging more than 260 deaths per week, according to new figures from the Royal College of Emergency Medicine (RCEM). The RCEM estimate is based on a large study of NHS patients published in the Emergency Medicine Journal in 2021, which found one excess death for every 72 patients who spent eight to 12 hours in an A&E department. Following a Freedom of Information audit of NHS trusts, the college has found that 65 per cent of people waiting 12 hours or more in A&E were patients waiting for a hospital bed. NHS data for England revealed that over 1.5 million patients waited 12 hours or more in major emergency departments last year. Based on the RCEM calculation, this indicates that over a million of those patients were waiting for a bed.

In a bid to address the ongoing deficit in staff in the UK's healthcare system, the National Health Service (NHS) has entered into a new workforce agreement with India. According to media reports, the healthcare service plans to hire 2,000 doctors from India on a fast-track basis to alleviate this pressing issue. It is learned that the NHS has set up training centres across many Indian cities such as Mumbai, Bangalore, Nagpur, Delhi, Gurugram, Indore, Mysore, Chennai, and Calicut to provide postgraduate training for the first batch of doctors. Post their training period (which ranges from six to 12 months), these doctors will be deployed at hospitals across Britain. They will also be exempted from the Professional and Linguistic Assessments Board (PLAB) examination that is otherwise mandatory for practising in the country.

Consumer healthcare group Haleon on Thursday announced that it has entered into a binding agreement for the sale of the ChapStick brand to Suave Brands Company, a company owned by American private equity firm Yellow Wood Partners. The British consumer healthcare company has agreed to sell its lip balm brand to Suave for about $430 million in cash and a minority interest in the buyer, valued at around $80 million. Haleon, which was spun off from the GSK Group in July 2022, said that cash proceeds from the sale would be used to pay down debt. ChapStick generated £112 million ($142.5 million) in revenue in 2023, said Haleon, adding that the sale is likely to close in the second quarter of 2024. Brian McNamara, Chief Executive Officer, Haleon, said: "Today's announcement is consistent with Haleon being proactive in managing our portfolio, and being rigorous and disciplined where there are opportunities for divestment. "While ChapStick is a great brand, much loved by consumers around the world, it is not a core focus for Haleon.

The final report of the Infected Blood Inquiry has been published today, bringing to light a devastating chapter in the history of the UK's healthcare system. The inquiry, which was launched by former Prime Minister Theresa May in 2017, examined how contaminated blood products infected over 30,000 NHS patients with deadly viruses, including HIV and Hepatitis C, between the 1970s and 1990s. Following the publication of the report, Prime Minister Rishi Sunak issued a formal apology on behalf of successive governments, acknowledging the state's significant failings. He stated that he finds it "impossible to comprehend" how victims felt when injected with deadly diseases through no fault of their own.

Health and Social Care Secretary, Wes Streeting, visited St Margaret's Hospital in Epping, West Essex, on Thursday (1 August) as part of an ongoing series of planned engagements with NHS trusts across England. Accompanied by NHS Chief Executive, Amanda Pritchard, Streeting observed how NHS staff are using innovative technology to monitor patients at home and prevent unnecessary hospital admissions. He met with staff from the hospital's Care Coordination Centre and the 'hospital at home' hub, which work to reduce unnecessary A&E admissions and facilitate quick and safe discharges home. Before the hospital tour, the health secretary met the trust's falls response team, which uses a specially equipped 'falls car' to assist patients who have fallen at home, preventing A&E visits. Later, Streeting visited the Ross Practice GP surgery in Harlow before holding a town hall event with health leaders in the region.